3 ms·
This isn't a particularly good article. Psychiatrists in the UK are cautiously optimistic about ketamine, and things like TCMS, but they're worried about the wi
by DanBC 8y ago
This isn't a particularly good article. Psychiatrists in the UK are cautiously optimistic about ketamine, and things like TCMS, but they're worried about the widespread off-label prescribing in the US, especially when that's decoupled from other measures such as talking therapy or psycho-social interventions.
> The suicide rate has been rising in the United States since the beginning of the century, [...] And yet no new classes of drugs have been developed to treat depression (and by extension suicidality) in about 30 years, since the advent of selective serotonin reuptake inhibitors like Prozac.
Lack of access to new drugs is common across countries, yet many countries have seen falling rates of suicide. What's different about the US?
> After her suicide attempt, Louise’s psychiatrist suggested she try ketamine. She agreed, and received an infusion intravenously. Within hours, her sense of well-being improved. The hospital discharged her. Back home, she discovered that going to the market was no longer a “herculean task.” Getting her car washed wasn’t an insurmountable chore. “Life was better,” she said. “Life was doable.”
This is exactly the kind of thing that was being said about prozac - these are wonder drugs that make you better than well, and the current drug licencing rules are outdated because Prozac should be available to everyone not just ill people.
Ketamine will end up being moderately useful to some people. It will save a few lives. It's probably not a wonder drug.
The article makes no mention of the low risk paradox. Most people who die by suicide will have been assessed as low risk of death by suicide shortly before they died. I'm curious if these people would be given ketamine or not. And that's the people who were seen by MH professionals before they died.
> Here’s a sobering fact: Some studies indicate that suicide risk peaks soon after patients have been discharged from a medical facility.
This is a well known phenomena, which is why NCISH in the UK includes this in their ten ways to improve safety in MH services https://sites.manchester.ac.uk/ncish/ https://sites.manchester.ac.uk/ncish/
"Patients discharged from psychiatric in-patient care should be followed up by the service within two to three days of discharge. A care plan should be in place at the time of discharge."
- derefr 8y ago> Lack of access to new drugs is common across countries They didn't say "new drugs", they said "new classes of drugs." The point they were trying to make was that innovation (by big-pharma researchers, at least) in the anti-depressant space has stalled.